Albumin human
Optison (albumin human) is a protein pharmaceutical. Albumin human was first approved as Optison on 1997-12-31.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Albuked, plasbumin, plasbumin, plasbumin, Albuminex, Alburx, Albutein, Buminate, flexbumin, Human albumin grifols, Idelvion, Kedbumin, N/a, Optison (discontinued: Albuminar, albuminar, albuminar, albuminar, Albutein, Chromalbin, Human albumin grifols)
CombinationsAdvate, Xyntha, xyntha solofuse
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Albumin human
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OPTISON | GE Healthcare | N-020899 RX | 1997-12-31 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| albumin (human) | Biologic Licensing Application | 2010-01-07 |
| albumin (human) 20% | Biologic Licensing Application | 2009-12-16 |
| albumin (human) 25% | Biologic Licensing Application | 2009-12-22 |
| albuminex | Biologic Licensing Application | 2024-12-31 |
| alburx | Biologic Licensing Application | 2009-01-06 |
| albutein | Biologic Licensing Application | 2008-07-01 |
| draximage maa | Biologic Licensing Application | 2024-02-13 |
| flexbumin | Biologic Licensing Application | 2007-06-15 |
| human albumin grifols | Biologic Licensing Application | 2010-09-08 |
| megatope | Biologic Licensing Application | 2023-09-01 |
Show 8 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ALBUMIN HUMAN, OPTISON, GE HEALTHCARE | |||
| 2028-05-09 | NPP | ||
| 2028-05-09 | NPP | ||
| 2028-05-09 | NPP | ||
| 2028-05-09 | NPP | ||
| 2028-05-09 | NPP | ||
| 2028-05-09 | NPP | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
3178 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 83 | 243 | 61 | 10 | 34 | 391 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 172 | 236 | 35 | 4 | 21 | 384 |
| Non-small-cell lung carcinoma | D002289 | — | — | 75 | 164 | 47 | 3 | 10 | 264 |
| Neoplasms | D009369 | — | C80 | 146 | 87 | 10 | 4 | 18 | 219 |
| Adenocarcinoma | D000230 | — | — | 66 | 115 | 33 | 3 | 6 | 188 |
| Carcinoma | D002277 | — | C80.0 | 42 | 117 | 28 | 4 | 10 | 180 |
| Triple negative breast neoplasms | D064726 | — | — | 36 | 97 | 29 | 1 | 3 | 148 |
| Lung neoplasms | D008175 | — | C34.90 | 42 | 90 | 22 | 3 | 9 | 147 |
| Squamous cell carcinoma | D002294 | — | — | 20 | 78 | 11 | 2 | 6 | 109 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 3 | 22 | 15 | 12 | 54 | 95 |
Show 168 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 40 | 53 | 15 | — | 3 | 101 |
| Fallopian tube neoplasms | D005185 | — | — | 24 | 31 | 14 | — | 2 | 64 |
| Esophageal neoplasms | D004938 | — | C15 | 18 | 48 | 3 | — | 5 | 64 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 26 | 29 | 8 | — | 4 | 62 |
| Recurrence | D012008 | — | — | 16 | 29 | 8 | — | 3 | 48 |
| Hepatic insufficiency | D048550 | — | — | 9 | 9 | 5 | — | 24 | 41 |
| Uterine cervical neoplasms | D002583 | — | — | 8 | 25 | 7 | — | 4 | 39 |
| Covid-19 | D000086382 | — | U07.1 | 6 | 13 | 5 | — | 15 | 37 |
| Endometrioid carcinoma | D018269 | — | — | 10 | 17 | 13 | — | — | 36 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 16 | 11 | 7 | — | 2 | 33 |
Show 172 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 13 | 3 | — | — | 3 | 18 |
| Wounds and injuries | D014947 | — | T14.8 | 6 | 5 | — | — | 10 | 17 |
| Prostatic neoplasms | D011471 | — | C61 | 8 | 7 | — | — | 3 | 16 |
| Left ventricular dysfunction | D018487 | — | — | 4 | 7 | — | — | 3 | 10 |
| Sclerosis | D012598 | — | — | 3 | 4 | — | — | 5 | 10 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 2 | — | — | 1 | 9 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 3 | — | — | 4 | 9 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 2 | 4 | — | — | 3 | 8 |
| Leukemia | D007938 | — | C95 | 3 | 3 | — | — | 2 | 7 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 2 | 4 | — | — | 2 | 7 |
Show 209 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | 1 | — | — | — | 7 | 8 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | — | — | — | 7 | 8 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | 6 | 7 |
| Hodgkin disease | D006689 | — | C81 | 5 | — | — | — | 1 | 6 |
| Malaria | D008288 | EFO_0001068 | B54 | 5 | — | — | — | — | 5 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 2 | — | — | — | 3 | 5 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | — | — | 4 | 5 |
| Multiple organ failure | D009102 | EFO_1001373 | — | 1 | — | — | — | 3 | 4 |
| Bariatric surgery | D050110 | — | — | 1 | — | — | — | 3 | 4 |
| B-cell lymphoma | D016393 | — | — | 3 | — | — | — | 1 | 4 |
Show 100 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 8 | 8 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | — | — | 8 | 8 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 7 | 7 |
| Gestational diabetes | D016640 | — | O24.4 | — | — | — | — | 7 | 7 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 6 | 6 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | — | — | 6 | 6 |
| Intestinal diseases | D007410 | — | K63.9 | — | — | — | — | 6 | 6 |
| Emergence delirium | D000071257 | — | — | — | — | — | — | 5 | 5 |
| Acidosis | D000138 | EFO_1000014 | E87.2 | — | — | — | — | 5 | 5 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 5 | 5 |
Show 300 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Albumin human |
| INN | perflutren |
| Description | Albuked (albumin human) is a protein pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 200-941-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201451 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | CK0N3WH0SR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 740,848 documents
View more details
Safety
Black-box Warning
Black-box warning for: Optison, Paclitaxel, Paclitaxel protein bound particles albumin bound, Paclitaxel protein-bound particles for injectable suspension (albumin-bound), Sterile diluent for allergenic extract
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,039 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use